José Estabil leads product and marketing activity at Cipherome, a venture-backed AI/genomics company personalizing medicine to limit adverse drug reactions. José catalyzed the launch of innovation centers in Moscow, Lisbon and Miami while at MIT and continues to serve on MIT’s Deshpande Innovation Center. Before moving to Boston, José led product management of three award winning diagnostics products in Silicon Valley (KLA). He started his career at IBM labs studying the "epidemiology" of circuits. José serves on the board of directors of VentureWell (RADx) and Latinos in Bio, an organization promoting access and inclusion of Latinxes in the life sciences.
Philip Empey, UPitt
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.